Aggiunta gestione mirata della temperatura nell'avvelenamento acuto da monossido di carbonio grave
Gestione mirata della temperatura combinata con l'ossigenoterapia iperbarica nell'avvelenamento acuto da monossido di carbonio: studio clinico multicentrico controllato randomizzato (studio TTM-COHB)
This randomized trial will investigate important neurocognitive clinical outcomes of patients with acute severe carbon monoxide poisoning (ASCOP) randomized to receive either therapeutic hypothermia or normothermia combined with hyperbaric oxygen therapy (HBO).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
CO-poisoned patients are identified by medical history and carboxyhemoglobin (CO-Hb) value >5% (>10% in smokers). Patients presenting with acute CO poisoning will receive one HBO. ASCOP is defined as mental status showing response to painful stimulus or unresponsiveness requiring intubation for airway protection and ventilation support at the emerency department, and persistence of depressed mental status despite the HBO. After HBO treatment, eligible patients who provide consent will be randomly allocated to receive hypothermia, or normothermia treatment administered in a open label fashion except for blinding of outcome assessor.
Outcome measures will be administered at 1 month and 6 months after CO exposure. In addition, we will examine the differences in serum markers and mortality between the hypothermia and normothermia groups.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Gangwon-do
-
Wŏnju, Gangwon-do, Corea del Sud, 26426
- Wonju Severance Christian Hospital
-
-
Incheon
-
Incheon, Incheon, Corea del Sud, 22332
- Inha University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- ≥ 19 years.
- Patients who received HBO within 24 hours for acute CO poisoning.
- Patients who meet the definition of ASCOP (Patients incapable verbal obey after HBO).
- Signed informed consent prior to study entry.
Exclusion Criteria:
- Cardiac arrest before HBO
- Previous neurocognitive disorders
- Life-threatening underlying disease (ex: advanced cancer)
- Evidence of co-ingestion of sedative or hypnotics confirmed by intravenous flumazenil administration or history taking at the emergency department
- Absolute contraindication for TH (active severe bleeding and profound shock not controlled by vasoactive drugs)
- No admission
- The significant co-ingested drug levels, which are alter the consciousness, is confirmed from the drug analysis lab
- Pregnancy
- Burns
- More than moderate burn or Inhalation burn
- Burns complicated by other trauma
- Electrical burn
- Burns in high risk patients (Patients with chronic underlying diseases (i.e DM, ESRD, liver cirrhosis, etc) which may cause delays or aggravate the wound healing)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Hypothermia group
Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours. |
Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours. |
|
Comparatore attivo: Normothermia group
For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent. |
Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Main neurocognitive outcome
Lasso di tempo: At 6 months after CO poisoning
|
Global Deterioration Scale [range 1 - 7 (worst score)] |
At 6 months after CO poisoning
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Neurocognitive outcome
Lasso di tempo: At 1 month after CO poisoning
|
Global Deterioration Scale [range 1 - 7 (worst score)] |
At 1 month after CO poisoning
|
|
Cerebral Performance Category
Lasso di tempo: At 1 month and 6 months after CO poisoning
|
Cerebral Performance Category [range 1 - 5 (worst score)] |
At 1 month and 6 months after CO poisoning
|
|
modified Rankin scale
Lasso di tempo: At 1 month and 6 months after CO poisoning
|
modified Rankin scale [range 0 - 6 (worst score)] |
At 1 month and 6 months after CO poisoning
|
|
Glasgow outcome scale
Lasso di tempo: At 1 month and 6 months after CO poisoning
|
Glasgow outcome scale [range 1 (worst score) - 5] |
At 1 month and 6 months after CO poisoning
|
|
mini-mental status exam
Lasso di tempo: At 1 month and 6 months after CO poisoning
|
mini-mental status exam |
At 1 month and 6 months after CO poisoning
|
|
Korean version of the Modified Barthel Index
Lasso di tempo: At 1 month and 6 months after CO poisoning
|
Korean version of the Modified Barthel Index |
At 1 month and 6 months after CO poisoning
|
|
Mortality in intensive care unit
Lasso di tempo: Through study completion, an average of 6 months
|
Number of participants with mortality in intensive care unit |
Through study completion, an average of 6 months
|
|
Mortality in intensive care unit
Lasso di tempo: Through study completion, an average of 6 months
|
Rate of participants with mortality in intensive care unit |
Through study completion, an average of 6 months
|
|
In-hospital mortality
Lasso di tempo: Through study completion, an average of 6 months
|
Number of participants with in-hospital mortality |
Through study completion, an average of 6 months
|
|
In-hospital mortality
Lasso di tempo: Through study completion, an average of 6 months
|
Rate of participants with in-hospital mortality |
Through study completion, an average of 6 months
|
|
Mortality
Lasso di tempo: At 1, 3, and 6 months after CO poisoning
|
Number of participants with all cause mortality |
At 1, 3, and 6 months after CO poisoning
|
|
Mortality
Lasso di tempo: At 1, 3, and 6 months after CO poisoning
|
Rate of participants with all cause mortality |
At 1, 3, and 6 months after CO poisoning
|
|
Length of stay in intensive care unit and hospital
Lasso di tempo: Through study completion, an average of 6 months
|
Length of stay in intensive care unit and hospital |
Through study completion, an average of 6 months
|
|
Pneumonia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Pneumonia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Shock
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Shock
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Bradycardia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with dropped heart rate indicated drug or interventions |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Bradycardia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with dropped heart rate indicated drug or interventions |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypokalemia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum K concentration <3.0 - 2.5 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypokalemia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum K concentration <3.0 - 2.5 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperkalemia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum K concentration >6.0 - 7.0 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperkalemia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum K concentration >6.0 - 7.0 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperglycemia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperglycemia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypophosphatemia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypophosphatemia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypomagnesemia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum magnesium <0.9 - 0.7 mg/dL |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypomagnesemia
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum magnesium <0.9 - 0.7 mg/dL |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged prothrombin Time International Normalized Ratio
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged prothrombin Time International Normalized Ratio
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged activated partial thromboplastin time
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged activated partial thromboplastin time
Lasso di tempo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
S100ß (serum)
Lasso di tempo: Within 14 days after CO exposure
|
Concentration of S100ß (serum) |
Within 14 days after CO exposure
|
|
Neuronal specific enolase (serum)
Lasso di tempo: Within 14 days after CO exposure
|
Concentration of neuronal specific enolase (serum) |
Within 14 days after CO exposure
|
|
Brain magnetic resonance image (MRI)
Lasso di tempo: Within 14 days after CO exposure
|
Number of participants with brain injury in brain MRI |
Within 14 days after CO exposure
|
|
Brain magnetic resonance image (MRI)
Lasso di tempo: Within 14 days after CO exposure
|
Rate of participants with brain injury in brain MRI |
Within 14 days after CO exposure
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Yong Sung Cha, MD, Wonju Severance Christian Hospital
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- TTM-COHB trial
- CR220011 (Altro identificatore: Wonju Severance Christian Hospital)
- 2021-04-043 (Altro identificatore: Inha University Hospital)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .